



Vaccine Stability Considerations to Enable Rapid Development and Deployment VIRTUAL WORKSHOP

Wednesday, March 24, 2021

10:30 am – 12:00 pm	Part 1
10:30 am – 10:35 am	Introduction and Welcome (Jianmei D. Kochling, Ph.D., M.S., Sanofi) (Kim HuynhBa, M.S., PMP, FAAPS, Pharmalytik LLC)
10:35 am – 11:05 am	Session 1: Vaccine Formulation Challenges in a Pandemic Setting (Lisa Kuelczo, Ph.D., National Institutes of Health (NIH))
11:05 am – 11:55 am	Session 2: Panel Discussion: Key Challenges to Find a Vaccine in a Global Pandemic (Lisa Kuelczo, Ph.D., National Institutes of Health (NIH)) (Michael Angelastro, Ph.D., BARDA) (Gayle Pulle, Ph.D., Health Canada) (Jianmei D. Kochling, Ph.D., M.S., Sanofi) (Kim HuynhBa, M.S., PMP, FAAPS, Pharmalytik LLC)
11:55 am – 12:00 pm	Closing Remarks
12:30 pm – 1:15 pm	Day One Virtual Networking Event
2:00 pm – 4:00 pm	Part 2
2:00 pm – 2:05 pm	Introduction and Welcome (Laure L. Larkin, MS, CPP, Johnson & Johnson) (Dilip R. Choudhury, Ph.D., Independent Consultant)
2:05 pm – 2:30 pm	Session 3: Covid-19 Vaccine EUA Stability Approach (Arjen Scholten, Ph.D., Janssen Vaccines and Prevention B.V.)
2:30 pm – 2:55 pm	Session 4: Analytical Characterization of a BEVS-derived Spike Protein Construct (Kartik Narayan, Ph.D., Sanofi Pasteur)

3:25 pm – 3:50 pm	Panel Discussion (Dilip R. Choudhury, Ph.D., Independent Consultant) (Laure L. Larkin, MS, CPP, Johnson & Johnson) (Gillian French, Ph.D., AstraZeneca) (Arjen Scholten, Ph.D., Janssen Vaccines and Prevention B.V.) (Kartik Narayan, Ph.D., Sanofi Pasteur)
3:55 pm – 4:00 pm	Closing Remarks

Thursday, March 25, 2021

10:30 am – 12:00 pm	Part 3
10:30 am – 10:35 am	Introduction and Welcome (Lori McCaig, Ph.D., Seagen, Inc.) (Nanda Subbarao, Ph.D., Biologics Consulting)
10:35 am – 11:00 am	Session 6: Principles and Practices of Vaccine Stability Modeling (Tim Schofield, CMC Sciences)
11:00 am – 11:30 am	Session 7: Taking Stability off the Critical Path of Product Development (Andrew Lennard, Ph.D., Amgen)
11:30 am – 11:55 am	Panel Discussion (Lori McCaig, Ph.D., Seagen, Inc.) (Nanda Subbarao, Ph.D., Biologics Consulting Group, Inc.) (Tim Schofield, CMC Sciences) (Andrew C. Lennard, Ph.D., Amgen Inc.) (Stephanie Ferrari, MS, Pfizer) (Julia O'Neill, MS, Moderna Inc.)
11:55 am – 12:00 pm	Closing Remarks
12:30 pm – 1:15 pm	Day Two Virtual Networking Event
2:00 pm – 4:00 pm	Part 4
2:00 pm – 2:05 pm	Introduction and Welcome (Yajie Zhang, Ph.D., Regeneron Pharmaceuticals) (Yan Wu, Ph.D., Merck)
2:05 pm – 2:45 pm	Session 8: Challenges of Vaccine Distribution and Deployment (Nada Sanders, Ph.D., Northeastern University)
2:45 pm – 3:20 pm	Session 9: The Last Mile: Ensuring Proper Storage and Handling at the Vaccination Center (Tony Reed, MD, Ph.D., MBA, CPE, Temple Health)

3:20 pm – 3:55 pm

Panel Discussion

(Yajie Zhang, Ph.D., Regeneron Pharmaceuticals)

(Yan Wu, Ph.D., Merck Sharp & Dohme)

(Nada Sanders, Ph.D., Northeastern University)

(Tony S. Reed, MD, PhD, MBA, CPE, Temple University Health System)

3:55 pm – 4:00 pm

Closing Remarks